Alphamab Oncology (FRA:3NK)
Germany
· Delayed Price · Currency is EUR 1.150
+0.050 (4.55%)
At close: Dec 4, 2025
Alphamab Oncology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Net Income | 232.81 | 166.34 | -210.59 | -325.72 | -412.42 | -427.77 | Upgrade
|
| Depreciation & Amortization | 71.4 | 77.03 | 69.12 | 55.19 | 41.1 | 30.13 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.92 | 0.25 | 0.1 | 0.01 | - | - | Upgrade
|
| Stock-Based Compensation | 1.85 | 2.53 | 5.72 | 13.29 | 8.17 | 32.73 | Upgrade
|
| Other Operating Activities | -29.24 | -46.93 | -75.19 | -82.62 | 5.17 | 13.53 | Upgrade
|
| Change in Accounts Receivable | -39.82 | -9.39 | 8.36 | -7.88 | -7.61 | - | Upgrade
|
| Change in Inventory | -16.92 | -3.06 | -14.11 | -6.73 | -13.59 | -18.4 | Upgrade
|
| Change in Accounts Payable | 27.55 | 8.56 | 1.26 | 31.09 | 44.71 | 23.92 | Upgrade
|
| Change in Unearned Revenue | 13.05 | 13.86 | -3.05 | 1.93 | 15.12 | 15.47 | Upgrade
|
| Change in Other Net Operating Assets | -5.13 | 3.15 | 15.55 | 21.14 | -1.25 | -16.78 | Upgrade
|
| Operating Cash Flow | 256.48 | 212.34 | -202.84 | -300.31 | -320.6 | -347.18 | Upgrade
|
| Capital Expenditures | -38.87 | -21.77 | -36.18 | -129.65 | -158.12 | -90.82 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.22 | 0.22 | - | - | - | - | Upgrade
|
| Investment in Securities | -504.23 | -139.34 | -39.52 | 946.14 | 664.22 | -1,464 | Upgrade
|
| Other Investing Activities | 46.22 | 67.97 | 57.6 | 34.26 | 68.16 | 30.99 | Upgrade
|
| Investing Cash Flow | -496.65 | -92.93 | -18.11 | 850.76 | 574.26 | -1,524 | Upgrade
|
| Long-Term Debt Issued | - | 127.25 | 465 | 401.07 | 692.47 | 110.35 | Upgrade
|
| Total Debt Issued | 218.62 | 127.25 | 465 | 401.07 | 692.47 | 110.35 | Upgrade
|
| Long-Term Debt Repaid | - | -207.93 | -552.89 | -692.95 | -313.97 | -141.51 | Upgrade
|
| Total Debt Repaid | -277.1 | -207.93 | -552.89 | -692.95 | -313.97 | -141.51 | Upgrade
|
| Net Debt Issued (Repaid) | -58.48 | -80.68 | -87.89 | -291.88 | 378.5 | -31.16 | Upgrade
|
| Issuance of Common Stock | 0.78 | 0.14 | 329.43 | 0.25 | 0.35 | 250.26 | Upgrade
|
| Repurchase of Common Stock | -9.19 | -9.19 | - | - | - | - | Upgrade
|
| Other Financing Activities | -8.16 | -9.23 | -23.46 | -19.28 | -14.94 | -32.52 | Upgrade
|
| Financing Cash Flow | -75.05 | -98.96 | 218.07 | -310.9 | 363.9 | 186.58 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.59 | 5.69 | 19.67 | 26.34 | 0.42 | 1.74 | Upgrade
|
| Net Cash Flow | -314.63 | 26.13 | 16.8 | 265.88 | 617.99 | -1,683 | Upgrade
|
| Free Cash Flow | 217.62 | 190.56 | -239.02 | -429.96 | -478.72 | -438 | Upgrade
|
| Free Cash Flow Margin | 27.69% | 29.77% | -109.26% | -257.70% | -327.84% | - | Upgrade
|
| Free Cash Flow Per Share | 0.22 | 0.19 | -0.25 | -0.46 | -0.51 | -0.47 | Upgrade
|
| Cash Interest Paid | 8.16 | 9.23 | 11.32 | 19.28 | 14.94 | 11.43 | Upgrade
|
| Levered Free Cash Flow | 130.57 | 139.12 | -186.64 | -332.02 | -330.88 | -391.52 | Upgrade
|
| Unlevered Free Cash Flow | 135.76 | 145.32 | -179.02 | -323.14 | -322.64 | -384.13 | Upgrade
|
| Change in Working Capital | -21.26 | 13.12 | 8.01 | 39.55 | 37.38 | 4.21 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.